Reply to Auclin et al. Comment on "Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176"

被引：0
作者：
Hopkins, Ashley M. [1 ]
Kichenadasse, Ganessan [1 ,2 ]
Abuhelwa, Ahmad Y. [1 ]
McKinnon, Ross A. [1 ]
Rowland, Andrew [1 ]
Sorich, Michael J. [1 ]
机构：
[1] Flinders Univ S Australia, Coll Med & Publ Hlth, Bedford Pk, SA 5042, Australia
[2] Flinders Med Ctr, Dept Med Oncol, Adelaide, SA 5042, Australia
来源：
CANCERS | 2021年 / 13卷 / 15期
关键词：
SURVIVAL; OUTCOMES;
D O I：
10.3390/cancers13153763
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 11 条
[1]   Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer [J].
Abuhelwa, Ahmad Y. ;
Kichenadasse, Ganessan ;
McKinnon, Ross A. ;
Rowland, Andrew ;
Hopkins, Ashley M. ;
Sorich, Michael J. .
CANCERS, 2021, 13 (09)
[2]   Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial (vol 13, 1176, 2021) [J].
Auclin, Edouard ;
Mezquita, Laura ;
Besse, Benjamin .
CANCERS, 2021, 13 (14)
[3]   Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial [J].
Hopkins, Ashley M. ;
Kichenadasse, Ganessan ;
Abuhelwa, Ahmad Y. ;
McKinnon, Ross A. ;
Rowland, Andrew ;
Sorich, Michael J. .
CANCERS, 2021, 13 (05) :1-9
[4]   Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab [J].
Hopkins, Ashley M. ;
Kichenadasse, Ganessan ;
Karapetis, Christos S. ;
Rowland, Andrew ;
Sorich, Michael J. .
EUROPEAN UROLOGY, 2020, 78 (04) :540-543
[5]   Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab [J].
Hopkins, Ashley M. ;
Kichenadasse, Ganessan ;
Karapetis, Christos S. ;
Rowland, Andrew ;
Sorich, Michael J. .
CLINICAL CANCER RESEARCH, 2020, 26 (20) :5487-5493
[6]   Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab [J].
Hopkins, Ashley M. ;
Kichenadasse, Ganessan ;
Garrett-Mayer, Elizabeth ;
Karapetis, Christos S. ;
Rowland, Andrew ;
Sorich, Michael J. .
CLINICAL CANCER RESEARCH, 2020, 26 (13) :3280-3286
[7]   Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer [J].
Kazandjian, Dickran ;
Gong, Yutao ;
Keegan, Patricia ;
Pazdur, Richard ;
Blumenthal, Gideon M. .
JAMA ONCOLOGY, 2019, 5 (10) :1481-1485
[8]   Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer [J].
Kichenadasse, Ganessan ;
Miners, John O. ;
Mangoni, Arduino A. ;
Rowland, Andrew ;
Hopkins, Ashley M. ;
Sorich, Michael J. .
JAMA ONCOLOGY, 2020, 6 (04) :512-518
[9]   Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer [J].
Mezquita, Laura ;
Auclin, Edouard ;
Ferrara, Roberto ;
Charrier, Melinda ;
Remon, Jordi ;
Planchard, David ;
Ponce, Santiago ;
Paz Ares, Luis ;
Leroy, Laura ;
Audigier-Valette, Clarisse ;
Felip, Enriqueta ;
Zeron-Medina, Jorge ;
Garrido, Pilar ;
Brosseau, Solenn ;
Zalcman, Gerard ;
Mazieres, Julien ;
Caramela, Caroline ;
Lahmar, Jihene ;
Adam, Julien ;
Chaput, Nathalie ;
Soria, Jean Charles ;
Besse, Benjamin .
JAMA ONCOLOGY, 2018, 4 (03) :351-357
[10]   Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials [J].
Sorich, Michael J. ;
Rowland, Andrew ;
Karapetis, Christos S. ;
Hopkins, Ashley M. .
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (08) :1440-1446
12